Key Market Indicator:
F&G: 56
25.562,75 NASDAQ · 48.877,01 DOW · 6.940,75 S&P · 4.894,06 Gold · 69,47 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
US54303L1044
Filter zurücksetzen
© Globe Newswire
29.01.2026
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Article
News Preview
Japan Patent Office (JPO) has granted Longeveron a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs)....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.01.2026
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Article
News Preview
Longeveron granted FDA Type C meeting ahead of Q3 2026 data readout of pivotal clinical trial for stem cell therapy in hypoplastic left heart syndrome....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.12.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Article
News Preview
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Week 2026....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
17.12.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
Article
News Preview
Longeveron granted US patent for method of treating female sexual dysfunction using its proprietary stem cell therapy laromestrocel....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
03.12.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
Article
News Preview
Longeveron Chief Science Officer and Chief Medical Officer selected as speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum (Dec 8-10)....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
Article
News Preview
Longeveron granted Canadian patent for method of using stem cells to treat patients with aging-related frailty and also for the treatment of NIDCM....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
Article
News Preview
Longeveron presents new MRI biomarker data linking neuroinflammation to clinical outcomes in patients with mild Alzheimer's disease at CTAD 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
Article
News Preview
Cellular therapy laromestrocel Phase 2 clinical trial data in Alzheimer's disease selected for poster presentation at CTAD 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
Article
News Preview
Longeveron issued US patent for method of treating aging-related frailty in patients with inflammaging using its proprietary stem cell therapy....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Article
News Preview
Longeveron to report 3Q25 financial results and host investor/analyst call/webcast on Tuesday, November 4, 2025 after close of US financial markets....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Article
News Preview
Dr. Joshua Hare, CSO and Exec Chairman interviewed on NPR's BioTech Nation, discussing potential breakthrough stem cell therapy for HLHS....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Article
News Preview
Longeveron will participate in the 4th Annual ROTH Healthcare Opportunities Conference October 9, 2025 in New York City....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
01.10.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
Article
News Preview
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Article
News Preview
Longeveron hosting partnering discussions for its Alzheimer's disease stem cell therapy program at Cell & Gene Meeting on the Mesa....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Announces Key Leadership Updates
Article
News Preview
Longeveron BOD appoints Interim CEO and Executive Chairman of BOD. Board plans to conduct a national search to identify a permanent CEO....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Article
News Preview
Longeveron will present and host investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended June 30, 2025 and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
Article
News Preview
Longeveron announces closing of up to $17.5 million public offering. Proceeds to support potential BLA readiness activities, among other items....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Announces Up To $17.5 Million Public Offering
Article
News Preview
Longeveron announces the pricing of a public offering of common stock and warrants....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.07.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Article
News Preview
Longeveron licenses patented stem cell technology from the University of Miami....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Article
News Preview
FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Appoints Than Powell as Chief Business Officer
Article
News Preview
Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.06.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Article
News Preview
Longeveron CEO Wa’el Hashad will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Attend BIO International Convention 2025
Article
News Preview
Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Article
News Preview
Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
Article
News Preview
Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Present at the 37th Annual Roth Conference
Article
News Preview
Longeveron to present at the Roth investor conference taking place March 17-18, 2025. Company fireside chat Tuesday, March 18th at 9:00am PT....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.02.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
Article
News Preview
Longeveron announces 2024 financial results and provides business update. Pivotal Phase 2b clinical trial achieves 90% enrollment....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
Article
News Preview
Longeveron to report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
Article
News Preview
WHO approved generic name laromestrocel for stem cell therapy Lomecel-B, being developed as potential treatment for Alzheimer's disease and HLHS....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.02.2025
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
Article
News Preview
Longeveron to present at the Emerging Growth Virtual Conference taking place February 18-19, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.12.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron to Present at Biotech Showcase 2025
Article
News Preview
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
Article
News Preview
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
Article
News Preview
Longeveron has appointed Devin Blass as Chief Technology Officer (CTO) and SVP of CMC, effective Dec 2, adding capabilities ahead of potential BLA filing....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Article
News Preview
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Article
News Preview
Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Article
News Preview
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24)....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Article
News Preview
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
Article
News Preview
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Article
News Preview
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Article
News Preview
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Article
News Preview
Longeveron to present at HC Wainwright global investment conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
Article
News Preview
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.07.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Article
News Preview
Longeveron announces closing of previously announced registered direct offering, raising $9 million in gross proceeds....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Neha Motwani Elected to Longeveron® Board of Directors
Article
News Preview
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
Article
News Preview
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
Article
News Preview
Longeveron raises $4.4 Million in gross proceeds from warrant exercise transaction to fund development of its cellular therapy Lomecel-B...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
Article
News Preview
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron® to Attend BIO International Convention 2024
Article
News Preview
Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.05.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron Announces Board of Directors Planned Transitions
Article
News Preview
Longeveron announces planned transitions on its Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Article
News Preview
Longeveron to report Q1 2024 financial results on May 14, 2024....
Themefolio
Profiler
Peergroup
© Newsfile
12.04.2021
ISIN: US54303L1044
Longeveron, Inc.
LGVN
LISTED
NASDAQ
SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan
Article
News Preview
New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, was recently the focus of coverage by leading financial news website and publisher, SmallCapsDaily. Longev...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 30.01.2026, Calendar Week 05, 30th day of the year, 335 days remaining until EoY.